Clinical Nurse Specialist in Casa Grande, AZ Accepting Medicare

1 Clinical Nurse Specialist nurses found. Showing 1 - 1

Kary L O'connor, CNS/CRNFA Clinical Nurse Specialist - Perioperative Medicare: Accepting Medicare Assignments Practice Location: 1114 E Yucca St, Casa Grande, AZ 85222 Phone: 520-836-3229    Fax: 520-836-4053

News Archive

Response Biomedical announces shareholder approval for $8 million private placement

Response Biomedical Corporation announced that at the Company's Special General Shareholders' Meeting held today in Vancouver, shareholders approved the private placement of an aggregate of 13,333,333 common shares, at a price of Cdn. $0.60 per Offered Share, to Caduceus Private Investments III, LP, OrbiMed Associates III, LP and Caduceus Asia Partners, LP for gross proceeds of approximately Cdn. $8 million.

NSABB calls for global guidelines for conducting, communicating research involving dangerous pathogens

NewScientist reports on the U.S. National Science Advisory Board for Biosecurity's (NSABB) recommendation that revised versions of two controversial studies on H5N1 avian flu be published in scientific journals, reversing its previous recommendation that the studies only be published if certain details were withheld. According to the news service, dissent among the board members over the issue has prompted the committee to "propose talks to draft global guidelines for doing and communicating work involving dangerous pathogens."

UC Davis Clinical Translational Science Center receives its third NIH award renewal

The UC Davis Clinical Translational Science Center (CTSC) received notice of its third National Institutes of Health (NIH) award renewal, a vote of confidence in the center's ability to advance outstanding research in human health.

Report: Major gains in effort to enroll children in public health care programs

The report issued by the Department of Health and Human Services found that the number of children eligible but not enrolled in Medicaid and the Children's Health Insurance Program fell. Meanwhile, HHS also awarded $40 million in grants for more outreach.

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

Read more Medical News

› Verified 7 days ago